Vitalhub Passes $100M ARR with 33% Revenue Growth
Vitalhub exceeded $100 million in annual recurring revenue and reported 33% year-over-year revenue growth in Q2 2026.
Key points
- Vitalhub achieved $101.5 million in annual recurring revenue with 33% year-over-year total revenue growth.
- The company holds $136.5 million in cash and investments with no debt, supporting its M&A strategy.
- Adjusted EBITDA margin reached 26%, while recurring revenue comprised 77% of total quarterly sales.
Vitalhub reported second-quarter revenue of $31.7 million, marking a 33% year-over-year increase. The company crossed a significant operational threshold by closing the quarter with annual recurring revenue of $101.5 million, driven by 10% organic growth.
Profitability metrics remained robust, with adjusted EBITDA reaching $8.2 million, or 26% of total revenue. Gross margin was reported at 79%, a slight decline from 81% in the prior year period, as the company integrated recent acquisitions into its core operations.
Revenue composition and margin trends
Recurring revenue accounted for 77% of the total, amounting to $24.5 million. This segment includes term licenses, maintenance, and support services. Virtual care term license revenue contributed $2.3 million, while perpetual license revenue added $800,000 to the bottom line.
Services, hardware, and other revenue grew to $4.1 million from $2.7 million in the same period last year. According to Benzinga, this mix reflects the company’s expanding digital solutions portfolio and integration capabilities across its client base.
Strong cash position supports M&A
Vitalhub ended the quarter with $136.5 million in cash and investments, carrying no debt. This liquidity provides significant flexibility for future mergers and acquisitions, which remain a central pillar of the company’s strategic growth plan.
Management has initiated a normal course issuer bid to repurchase shares, balancing capital allocation between buybacks and inorganic growth. The company continues to integrate acquisitions such as Buddy Healthcare, Induction, and Novari to enhance its service offerings in the UK and Canadian markets.
AI roadmap and market challenges
The company has launched an AI roadmap focused on protocoling solutions and transcription services. Management expects these integrations to positively impact revenue by the end of 2027, leveraging automation to improve efficiency and customer engagement.
Operational challenges include customer suspensions linked to the UK market’s Palantir contract situation. Despite these headwinds, leadership remains optimistic about resolving issues and expanding the patient care coordination platform into new regions, including potential US market entry.
